Skip to main
TNYA

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tenaya Therapeutics Inc. is demonstrating significant scientific progress with promising data from clinical cohorts, indicating potential improvements in key cardiac metrics like left ventricular mass index (LVMI) and left ventricular posterior wall thickness (LVPWT), which could pave the way for accelerated approval of its therapies. The company has increased its projected chances of success for its lead product candidates, TN-201 and TN-401, suggesting improved confidence among analysts regarding their development paths. Additionally, early biomarker data and durable clinical outcomes in patient cohorts support a positive safety profile and overall therapeutic efficacy, enhancing the company's position in the competitive biotech landscape focused on heart disease treatments.

Bears say

Tenaya Therapeutics's stock outlook is negatively impacted by potential delays in transitioning its preclinical assets into clinical trials, which could harm market sentiment and lead to downward revisions in financial estimates. The company faces inherent risks associated with emerging safety signals related to immune reactions during clinical studies, which could further exacerbate investor concerns. Additionally, any deficiencies in developing adequate manufacturing capacity may impose substantial constraints on Tenaya's operational forecasts, limiting its ability to meet market demands.

Tenaya Therapeutic (TNYA) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Tenaya Therapeutic (TNYA) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.